Eli Lilly’s retatrutide can help shed up to 60 pounds of body weight

A trial showed upadacitinib (Rinvoq) reduced disease severity in palmoplantar pustulosis (PPP) vs. placebo. The study met feasibility criteria, with 95% adherence and 94.7% acceptability. Mean PP-PASI scores dropped from 20.3 to 4.6 with upadacitinib, vs. 18.0 to 15.4 with placebo. Common side effects included headache and acne. The study was presented at EADV 2026 and funded by the UK's National Institute for Health and Care Research.

Eli Lilly's phase 2 trial showed that combining eloralintide (an investigational amylin agonist) with tirzepatide (Mounjaro/Zepbound) led to significant weight loss (up to 23.3%) and HbA1c reduction (up to 2.9 percentage points) in adults with type 2 diabetes. The combination therapy outperformed tirzepatide alone. Lilly plans a phase 3 trial with a co-formulated injection.

Sanofi & Regeneron expanded their immunology partnership for up to $8B. Novo Nordisk acquired rights to a drug from Hengrui Pharma for up to $2.6B. Telix Pharmaceuticals to acquire ITM Isotope for up to $2.35B. Merck licensed a cancer drug from SciBrunch for up to $2.13B. Genentech partnered with Earendil Labs for up to $1.5B. GSK acquired a hepatic program from Wave Life Sciences. Lundbeck may acquire Xeris Biopharma.

Eli Lilly presented data at the EASD conference. Foundayo (orforglipron) showed cardiovascular safety and superior weight/glycemic outcomes vs. insulin glargine. EloraTZP, a combo of eloralintide and Zepbound, demonstrated greater weight loss and A1C reduction. Ebglyss (lebrikizumab) met endpoints for hand/foot atopic dermatitis. LLY competes with Novo in GLP-1 market.

Eli Lilly's experimental drug, retatrutide, showed up to 28.3% weight loss in late-stage trials, outperforming Ozempic's typical results. The drug targets three hormone pathways, unlike Ozempic's single pathway. Retatrutide is not yet approved and lacks direct comparison trials. Eli Lilly plans to submit it for U.S. regulatory review in 2027.

Eli Lilly received approval to build a $3 billion pharmaceutical plant in Katwijk, Netherlands, focusing on diabetes and weight-loss medicines. The project, bringing 500 jobs, was approved by the municipal council despite local opposition. Additional permits are needed for production and wastewater discharge. The company cited proximity to airports and the Leiden Bio Science Park as key factors for the location.